Swiss biotech health, aging and longevity company Timeline has raised CHF 56M ($66 million) in series D financing, including strategic investments from L’Oréal and Nestlé.
The investment interest centers on Timeline's proprietary technology, Mitopure, which "unlocks a precise dose of the rare urolithin A molecule and promotes healthy aging."
According to a study in Rejuvenation Research, "urolithin A significantly increased type I collagen expression and reduced matrix metalloproteinase 1 (MMP-1) expression. Urolithin A also reduced intracellular reactive oxygen species, which may be partially due to activation of the Nrf2-mediated antioxidative response."
In applications, Mitopure boosts cellular longevity by recycling and renewing the mitochondria, which is "essential for maintaining cellular energy which supports muscle strength, cognition, immune resilience, skin vitality and other important benefits," per Timeline.
The intended result is an expanded healthspan, as well as associated claims, including:
- Reenergized skin cells
- Defense against intrinsic and extrinsic aging factors (supporting collagen organization and assembly, as well as protection from photoaging)
- Visible reduction in wrinkle depth within 2 weeks
Clinically proven to be kind to skin while supporting an optimal environment for skin-cell healthspan.
The latest funding will allow Timeline to invest in its science, product categories and markets, including food, beauty and health.
"This strategic collaboration reflects the breakthrough multidimensional approach that we've always believed is necessary to make meaningful advancements for longevity and healthspan," said Patrick Aebischer, co-founder and chairman of Timeline “I want to thank L’Oréal, Nestlé and our longstanding investors for their commitment to longevity solutions rooted in the highest level of science”.
“Longevity is about living healthier for longer and L’Oréal has been working for a decade to understand and anticipate what this could mean for beauty,” said Barbara Lavernos, deputy CEO and in charge of research, innovation and technology, L’Oréal. “Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analyzing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”
"We have been an investor in Timeline since 2019 and continue to be very impressed with the team and stand behind the exponential potential that the Mitopure technology holds for nutrition to help people age better,” said Anna Mohl, CEO of Nestlé Health Science. “We’re excited to have L’Oréal join as an investor and strategic partner to bring this technology to new heights and extend its applications.”
